Sponsor:
Bambusa Therapeutics
Code:
NCT06944925
Conditions
Chronic Obstructive Pulmonary Disease
Eligibility Criteria
Sex: All
Age: 18 - 70+
Healthy Volunteers: Accepted
Interventions
BBT002
Placebo
Brief summary:
Conditions
Chronic Obstructive Pulmonary Disease
Study ID
NCT06944925
Start date
May 8, 2025
Status verified date
Jun, 2026
Completion date
Jul 31, 2027
Anticipated
Primary completion date
Jan 31, 2027
Anticipated
Eligibility Criteria
Sex: All
Age: 18 - 70+
Healthy Volunteers: Accepted
Enrollment
286 participants
Anticipated
Allocation
Randomized
Intervention Model
Sequential
Primary purpose
Treatment
Arms
experimental: Part A: BBT002
experimental: Part B: BBT002
experimental: Part C: BBT002
placebo comparator: Part A: Placebo
placebo comparator: Part B: Placebo
placebo comparator: Part C: Placebo
placebo comparator: Part D: Placebo
placebo comparator: Part E: Placebo
placebo comparator: Part F: Placebo
placebo comparator: Part G: Placebo
experimental: Part D: BBT002
experimental: Part E: BBT002
experimental: Part F: BBT002
experimental: Part G: BBT002
Interventions
BBT002
Placebo
Primary outcome measure
Central contacts
Locations
Equity Medical Bowling Green
Recruiting
Bowling Green, Kentucky, United States, 42104
Contacts
Principal Investigator:
Dr. James Allred
Equity Medical LLC
Recruiting
New York, New York, United States, 10023
Contacts
Principal Investigator:
Dr. Monalyn Zousias
Sponsor
Bambusa Therapeutics
Last update posted
Jul 1, 2026
Last verified
Jun, 2026
Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by Bambusa Therapeutics on 2026-07-01.